Cipla and Qilu Partner for US Keytruda Biosimilar
India's Cipla and China's Qilu Pharmaceutical have formed an exclusive partnership to launch a biosimilar version of Merck's cancer drug Keytruda in the United States market. Under the agreement, Qilu handles development and manufacturing while Cipla manages commercialization.
Xurve View
Insights:
Xurve View
CIPLA LTD has partnered with Qilu Pharmaceutical to launch a biosimilar version of Merck's cancer therapy Keytruda in the United States market. The deal joins India's commercial footprint with China's manufacturing capabilities ahead of patent expirations. Merck faces patent cliffs for its top-selling drug as global competitors prepare lower-cost alternatives.
